Literature DB >> 18660993

TNF/TNFR1 signaling up-regulates CCR5 expression by CD8+ T lymphocytes and promotes heart tissue damage during Trypanosoma cruzi infection: beneficial effects of TNF-alpha blockade.

Karina Kroll-Palhares1, Jaline Coutinho Silvério, Andrea Alice da Silva, Vladimir Michailowsky, Ana Paula Marino, Neide Maria Silva, Cristiano Marcelo Espinola Carvalho, Luzia Maria de Oliveira Pinto, Ricardo Tostes Gazzinelli, Joseli Lannes-Vieira.   

Abstract

In Chagas disease, understanding how the immune response controls parasite growth but also leads to heart damage may provide insight into the design of new therapeutic strategies. Tumor necrosis factor-alpha (TNF-alpha) is important for resistance to acute Trypanosoma cruzi infection; however, in patients suffering from chronic T. cruzi infection, plasma TNF-alpha levels correlate with cardiomyopathy. Recent data suggest that CD8-enriched chagasic myocarditis formation involves CCR1/CCR5-mediated cell migration. Herein, the contribution of TNF-alpha, especially signaling through the receptor TNFR1/p55, to the pathophysiology of T. cruzi infection was evaluated with a focus on the development of myocarditis and heart dysfunction. Colombian strain-infected C57BL/6 mice had increased frequencies of TNFR1/p55+ and TNF-alpha+ splenocytes. Although TNFR1-/- mice exhibited reduced myocarditis in the absence of parasite burden, they succumbed to acute infection. Similar to C57BL/6 mice, Benznidazole-treated TNFR1-/- mice survived acute infection. In TNFR1-/- mice, reduced CD8-enriched myocarditis was associated with defective activation of CD44+CD62Llow/- and CCR5+ CD8+ lymphocytes. Also, anti-TNF-alpha treatment reduced the frequency of CD8+CCR5+ circulating cells and myocarditis, though parasite load was unaltered in infected C3H/HeJ mice. TNFR1-/- and anti-TNF-alpha-treated infected mice showed regular expression of connexin-43 and reduced fibronectin deposition, respectively. Furthermore, anti-TNF-alpha treatment resulted in lower levels of CK-MB, a cardiomyocyte lesion marker. Our results suggest that TNF/TNFR1 signaling promotes CD8-enriched myocarditis formation and heart tissue damage, implicating the TNF/TNFR1 signaling pathway as a potential therapeutic target for control of T. cruzi-elicited cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18660993     DOI: 10.1590/s0074-02762008000400011

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  19 in total

1.  IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of Trypanosoma cruzi infection.

Authors:  Ester Roffê; Antonio Gigliotti Rothfuchs; Helton C Santiago; Ana Paula M P Marino; Flavia L Ribeiro-Gomes; Michael Eckhaus; Lis R V Antonelli; Philip M Murphy
Journal:  J Immunol       Date:  2011-12-12       Impact factor: 5.422

2.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 3.  Interferon-γ and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy.

Authors:  Ludmila Rodrigues Pinto Ferreira; Amanda Farage Frade; Monique Andrade Baron; Isabela Cunha Navarro; Jorge Kalil; Christophe Chevillard; Edecio Cunha-Neto
Journal:  World J Cardiol       Date:  2014-08-26

4.  Changes in genital tract immune cell populations after initiation of intrauterine contraception.

Authors:  Sharon L Achilles; Mitchell D Creinin; Kevin A Stoner; Beatrice A Chen; Leslie Meyn; Sharon L Hillier
Journal:  Am J Obstet Gynecol       Date:  2014-05-13       Impact factor: 8.661

5.  TNF-α is involved in the abnormal thymocyte migration during experimental Trypanosoma cruzi infection and favors the export of immature cells.

Authors:  Ana Rosa Pérez; Luiz Ricardo Berbert; Ailin Lepletier; Silvia Revelli; Oscar Bottasso; Suse Dayse Silva-Barbosa; Wilson Savino
Journal:  PLoS One       Date:  2012-03-26       Impact factor: 3.240

6.  Increased CD4+/CD8+ double-positive T cells in chronic Chagasic patients.

Authors:  Nicolas A Giraldo; Natalia I Bolaños; Adriana Cuellar; Fanny Guzman; Ana Maria Uribe; Astrid Bedoya; Natalia Olaya; Zulma M Cucunubá; Nubia Roa; Fernando Rosas; Víctor Velasco; Concepción J Puerta; John M González
Journal:  PLoS Negl Trop Dis       Date:  2011-08-23

7.  Different infective forms trigger distinct immune response in experimental Chagas disease.

Authors:  Paula Melo de Abreu Vieira; Amanda Fortes Francisco; Evandro Marques de Meneses Machado; Nívia Carolina Nogueira; Kátia da Silva Fonseca; Alexandre Barbosa Reis; Andrea Teixeira-Carvalho; Olindo Assis Martins-Filho; Washington Luiz Tafuri; Cláudia Martins Carneiro
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

8.  Inducible nitric oxide synthase in heart tissue and nitric oxide in serum of Trypanosoma cruzi-infected rhesus monkeys: association with heart injury.

Authors:  Cristiano Marcelo Espinola Carvalho; Jaline Coutinho Silverio; Andrea Alice da Silva; Isabela Resende Pereira; Janice Mery Chicarino Coelho; Constança Carvalho Britto; Otacílio Cruz Moreira; Renato Sergio Marchevsky; Sergio Salles Xavier; Ricardo Tostes Gazzinelli; Maria da Glória Bonecini-Almeida; Joseli Lannes-Vieira
Journal:  PLoS Negl Trop Dis       Date:  2012-05-08

9.  Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.

Authors:  Cristián Navarrete-Dechent; Daniela Majerson; Marisa Torres; Daniela Armijo; Mahir Patel; Alan Menter; Claudia de la Cruz
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

Review 10.  Chagas' disease: an update on immune mechanisms and therapeutic strategies.

Authors:  Silvia Beatriz Boscardin; Ana Claudia Troccoli Torrecilhas; Romina Manarin; Silvia Revelli; Elena Gonzalez Rey; Renata Rosito Tonelli; Ariel Mariano Silber
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.